Neuland Laboratories Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1oav1l8emxeyyw45jwwqsau5.pdf

Key Takeaways


CMS: The Quarter's Engine

Saharsh Davuluri: "the patent expiries only start after 2030. So, the other comfort that we draw from our CMS pipeline is that next 7 years or so we should continue to see the exclusivity benefit us."

GDS & the Specialty Mix


Balance Sheet & Capital Allocation

Saharsh Davuluri: "the decision to make CAPEX investments based on visibility that we get from customers is actually a position of privilege that we have put ourselves over the years of building this business."

Peptides: A Long Gestation

Saharsh Davuluri: "I think it is fair to also admit that the business itself has not contributed significantly to us. I would probably attribute that to two things. One is could we have put in a greater emphasis in terms of development capabilities and maybe develop more molecules, the answer to that is definitely yes..."

Operating Model & Competitive Position

Sucheth Davuluri: "we have hardly lost a customer in the last two decades, so I think customer is the center of our focus"

Guidance & Commitments

CommitmentSpecificsTimeline
Regular CAPEX₹100-₹120 crores annuallyOngoing
Growth CAPEX decisionSome action expected; needs board placementNext 2-4 quarters
CMS pipeline exclusivityPatent expiries only after 2030Next ~7 years
Unit 3 capacity creationCan create capacity within 12 months of decision12 months from decision
CMS commercial moleculesMaybe 2-3 more molecules could get commercializedNext 2 years
Peptide revenueMusic will be heard when business comes inNo timeline (lead indicators only)

Key Metrics

MetricQ2 FY24
Total income₹420.8 cr, vs ₹293.9 cr in Q2 FY23
Gross margin59.8%, vs 56.2% in Q2 FY23 and 55.2% in Q1 FY24
Profit after tax₹89.1 cr, vs ₹38.3 cr in Q2 FY23
EPS₹69.4 per share
Free cash flow₹128.8 cr (H1 FY24)
Net debt positionnegative ₹39.4 cr, more than a zero-debt company
Working capital cycle102 days, improved from 118 days in Q1 FY24
CAPEX invested₹43 cr (during the period)
Regular CAPEX guidance₹100–₹120 cr annually
CMS share of topline55%, up from 45% (implied jump)
Unit 3 utilization60%–65% of current installed capacity
CMS commercial molecules actively contributing5 or 6
Phase-2 to commercialization conversion rate25%, roughly one in four molecules
CMS pipeline patent expiryafter 2030, providing exclusivity for the next 7 years or so